Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial-Reference-Cited by-同舟云学术

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

Published:2008-10 Issue:10 Volume:7 Page:903-914
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Mikol Daniel D,Barkhof Frederik,Chang Peter,Coyle Patricia K,Jeffery Douglas R,Schwid Steven R,Stubinski Bettina,Uitdehaag Bernard MJ

Publisher

Elsevier BV

Subject

Clinical Neurology

Reference32 articles.

1. The immunopathology of multiple sclerosis: an overview;Lassmann;Brain Pathol,2007

2. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination;Lucchinetti;Ann Neurol,2000

3. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis;Lublin;Neurology,1996

4. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis;Lancet,1998

5. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group;Johnson;Neurology,1995

Cited by 403 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sclerosi multipla: trattamenti di base;EMC - Neurologia;2024-08

2. Do efficacy results obtained from randomized controlled trials translate to effectiveness data from observational studies for relapsing–remitting multiple sclerosis?;Pharmacoepidemiology and Drug Safety;2024-05

3. Advances in Multiple Sclerosis Neurotherapeutics, Neuroprotection, and Risk Mitigation Strategies;Neurologic Clinics;2024-02

4. Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives;Neurology and Therapy;2024-01-11

5. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-01-04